Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.70 |
| ▸ | NAMPT | P43490 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.53 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.52 |
| ▸ | ACACB | O00763 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4820829 | 0.84 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL7262807 | 0.81 | CA2 (0.55) | MAPK14NAMPT | |
| SCHEMBL178383 | 0.80 | MMP13 (0.71) | MAPK14KCNH2POLB | |
| SCHEMBL17744944 | 0.79 | MLYCD (0.62) | MAPK14NAMPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4492779 | 0.78 | MAPK14 (0.57) | MAPK14NAMPTMEN1KMT2ACYP3A4 | |
| SCHEMBL12368426 | 0.78 | ALDH1A1 (0.65) | NAMPTMEN1KMT2AALDH1A1NFKB1 | |
| SCHEMBL15317662 | 0.78 | MAPK14 (0.57) | MAPK14MEN1KMT2AALDH1A1NFKB1 | |
| SCHEMBL17847332 | 0.78 | MAPK14 (0.57) | MAPK14NAMPTPOLBACACB | |
| SCHEMBL3262619 | 0.77 | MAPK14 (0.56) | MAPK14NAMPTMEN1KMT2A | |
| SCHEMBL7478908 | 0.77 | ALDH1A1 (0.59) | MEN1KMT2AALDH1A1NFKB1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581202-A2 | METHODS FOR THE TREATMENT OF PAIN AND TRAUMATIC INJURY USING BENZAMIDES AND COMPOSITIONS CONTAINING THE SAME | Renovis, Inc. (US) | 2005-10-05 | — | — | EP | claimed |
| US-20040167226-A1 | Methods for the treatment of pain and traumatic injury using benzamides and compositions containing the same | RENOVIS, INC. | 2004-08-26 | — | — | US | claimed |
| WO-2004060286-A2 | METHODS FOR THE TREATMENT OF PAIN AND TRAUMATIC INJURY USING BENZAMIDES AND COMPOSITIONS CONTAINING THE SAME | RENOVIS, INC. (US) | 2004-07-22 | — | — | WO | claimed |
| EP-1581202-A2 | METHODS FOR THE TREATMENT OF PAIN AND TRAUMATIC INJURY USING BENZAMIDES AND COMPOSITIONS CONTAINING THE SAME | Renovis, Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040167226-A1 | Methods for the treatment of pain and traumatic injury using benzamides and compositions containing the same | RENOVIS, INC. | 2004-08-26 | — | — | US | disclosed |
| WO-2004060286-A2 | METHODS FOR THE TREATMENT OF PAIN AND TRAUMATIC INJURY USING BENZAMIDES AND COMPOSITIONS CONTAINING THE SAME | RENOVIS, INC. (US) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167226-A1 | Methods for the treatment of pain and traumatic injury using benzamides and compositions containing the same | CNR1, NAA50, CNR2 | MAPK14 2557/4885NAMPT 2068/4885MEN1 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.